# Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis

> **NCT03320434** · PHASE2 · COMPLETED · sponsor: **ORA, Inc.** · enrollment: 120 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** PRT-2761 0.5%
- **DRUG:** PRT-2761 1%
- **DRUG:** Patanol
- **DRUG:** Pred-forte
- **DRUG:** PRT-2761 0%

## Key facts

- **NCT ID:** NCT03320434
- **Lead sponsor:** ORA, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-13
- **Primary completion:** 2018-02-16
- **Final completion:** 2018-02-18
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2022-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03320434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03320434, "Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03320434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*